60 Degrees Pharmaceuticals, Inc.
SXTP- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001946563
No open-market purchases or sales by 60 Degrees Pharmaceuticals, Inc. insiders were filed in the last 90 days; 8 institutions reported holding it in 13F filings for Q2 2026, worth $614.8K in total; no superinvestor holds it.
Other share classesSXTPW
Key figures
- Market capClose on Nov 11, 2026
- $1.83M
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, 0 vs. previous quarter
- 8
- 13F valueReported value at the end of Q2 2026
- $614.8K
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- $1.01M
- +65.5% year over year
- Net income, FY2025
- -$7.37M
- No comparable prior period
- Free cash flow, FY2025
- -$6.99M
- No comparable prior period
- Revenue, Q2 FY2026
- $207.9K
- +106.0% year over year
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 255.1K
- Shares sold short
- Change
- +119.7K
- +88.4% vs. previous
- Days to cover
- 1.00
- At average daily volume
Superinvestors holding SXTP, Q2 2026
Go to the superinvestors tabNo superinvestor reported holding SXTP at the end of Q2 2026.
Latest insider trades
See all insider tradesOpen-market purchases and sales by 60 Degrees Pharmaceuticals, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jun 15, 2026 (view filing) | Jun 12 | 3 days | Dow Geoffrey SPresident and CEO | PPurchase | +7.35K | $1.38 | +$10.1K | +43.8%24.1K after | |
| Dec 16, 2025 (view filing) | Dec 15 | 1 day | Dow Geoffrey SPresident and CEO | PPurchase | +9.67K | $0.80 | +$7.74K | +19.4%59.6K after | |
| Dec 12, 2025 (view filing) | Dec 10-11 | 2 days | Dow Geoffrey SPresident and CEO | PPurchase | +13.0K | $0.9416 | +$12.2K | +35.0%49.9K after | 2 lots |
| Jun 5, 2025 (view filing) | Jun 3 | 2 days | Xu CherylDirector | PPurchase | +5.00K | $2.88 | +$14.4K | +46.2%15.8K after | 2 lots |
| Dec 18, 2024 (view filing) | Dec 12-16 | 6 daysLate | Xu CherylDirector | PPurchase | +13.0K | $1.65 | +$21.4K | +31.6%54.1K after | 7 lots |
| Dec 9, 2024 (view filing) | Dec 5-9 | 4 days | Dow Geoffrey SPresident and CEO | PPurchase | +74.0K | $1.21 | +$89.7K | +358.5%94.6K after | 3 lots |
| Nov 21, 2024 (view filing) | Nov 19-21 | 2 days | Dow Geoffrey SPresident and CEO | PPurchase | +7.00K | $0.9079 | +$6.36K | +51.4%20.6K after | 3 lots |
| Sep 11, 2024 (view filing) | Aug 27 | 15 daysLate | Xu CherylDirector | PPurchase | +5.00K | $1.70 | +$8.50K | +13.9%41.1K after | |
| Feb 2, 2024 (view filing)3:33 PM ET | Jan 31 | 2 days | Dow Geoffrey SPresident and CEO | PPurchase | +26.0K | $0.375 | +$9.74K | +3.8%703.6K after | |
| Feb 2, 2024 (view filing)3:33 PM ET | Jan 31 | 2 days | Dow Geoffrey SPresident and CEO | PPurchase | +26.0K | $0.01 | +$259.74 | –26.0K after | Derivative |
Top 10 13F holders, Q2 2026
See all 8 holdersThe largest institutional positions in 60 Degrees Pharmaceuticals, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Kathmere Capital Management, LLC | 265,100 | $466.6K | 0.02% | +120,417+83.2% | Added |
| Citadel Advisors LLC | 22,362 | $39.4K | 0.00% | +22,362 | New |
| XTX Topco Ltd | 17,639 | $31.0K | 0.00% | +17,639 | New |
| Kovack Advisors, Inc. | 15,000 | $26.4K | 0.00% | +15,000 | New |
| Geode Capital Management, LLC | 14,551 | $25.6K | 0.00% | −1,744−10.7% | Reduced |
| UBS Group AG | 13,592 | $23.9K | 0.00% | −17,818−56.7% | Reduced |
| Barclays PLC | 1,052 | $1.85K | 0.00% | −804−43.3% | Reduced |
| Advisor Group Holdings, Inc. | 25 | $44 | 0.00% | 00.0% | Unchanged |
Holders of 5% or more of SXTP
See all 5 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of 60 Degrees Pharmaceuticals, Inc..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Knight Therapeutics Inc. | 13G | 19.85%658.6K shares | +19.85 ppfrom 0.00% | Nov 13, 20243 filings | Jul 29, 2026 | SEC |
| Intracoastal Capital, LLC | 13G/A | 9.99%455.5K shares | 0.00 ppfrom 9.99% | Feb 3, 20254 filings | Nov 7, 2025 | SEC |
| Intracoastal Capital, LLC | 13G/A | 9.99%390.3K shares | +0.89 ppfrom 9.10% | May 13, 20262 filings | Nov 10, 2026 | SEC |
| CVI Investments, Inc. | 13G/A | 7.00%197.9K shares | −2.90 ppfrom 9.90% | Jul 22, 20253 filings | May 15, 2026 | SEC |
| Lind Global Fund III LP | 13G | 5.45%191.6K shares | New | Aug 5, 20261 filing | Aug 5, 2026 | SEC |